Briobacept
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3) and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) [1][2].
Product Specifications
CAS Number
869881-54-9
Product Name Alternative
BR 3FC
UNSPSC
12352203
Target
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/briobacept.html
Purity
97.66
Solubility
10 mM in DMSO
Smiles
[Briobacept]
Molecular Weight
(65.75 kDa)
References & Citations
[1]Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2) . Reumatol Clin. 2012 Sep-Oct;8 (5) :263-9. |[2]Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22 (33) :3152-3154. |[3]La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10 (11) :1555-61. |[4]Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17 (4) :515-24.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
126013-FITC 100 µL
DR4 (Death Receptor 4, Apo2, CD261, CD261 Antigen, Cytotoxic Ligand TRAIL Receptor, Cytotoxic TRAIL Receptor, MGC9365, T10A, TNF Related Apoptosis Inducing Ligand Receptor 1, TRAIL Receptor 1, TRAIL R1, TRAILR1, TRAIL-R1, TRAILR-1, Tumor Necrosis Factor Receptor Superfamily Member 10a, TNFRSF10A) (FITC)
Sign In for Pricing
View Details